Avricore Health Inc (VANC) Gross Profit Margin starting from the fourth quarter 2024 to fourth quarter 2023, Profitability Trends and Ranking, Fundamental Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Gross Margin
• EBITDA Margin
• Operating Margin
• Net Margin
• Pre-Tax Margin
• Effective Tax Rate
• Free Cash Flow Margin
• Cash Flow Margin
Avricore Health Inc   (VANC)


Avricore Health Inc 's Gross Profit Margin by quarter

Trends, Rankings, Statistics


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

VANC Gross Profit Margin (Dec 31 2024)
Q4 		0
Q3 		0
Q2 		0
Q1 		(Dec 31 2023)
Q4
Y / Y Revenue Change 79.01 %
Seq. Revenue Change -
Revenue In Millions $3.44
Gross Profit Margin 41.87 %
Gross Profit Margin Total Ranking # 2240
Gross Profit In Millions $1.44
Y / Y Gross Profit Change 56.25 %
Seq. Gross Profit Change -


Commenting fourth quarter 2024 Gross Profit Margin



Observing fourth quarter 2024 results within Major Pharmaceutical Preparations industry 144 other companies have achieved higher Gross Profit Margin. While Gross Profit Margin overall ranking has deteriorated relative to the three months before, from to 2240.
Learn about Gross Margin
VANC's Gross Profit Margin fourth quarter 2024 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 145
Healthcare Sector # 382
Overall # 2218

Gross Profit Margin Statistics
High Average Low
47.97 % 35.13 % 24.85 %
(Dec 31 2023)   (Dec 31 2021)


VANC Gross Income Trends • More of VANC's Profitabilty Ratios • VANC Stock Quotes and Charts


Other Gross Profit Margin Profitability Ratios
VANC's Cumulative Gross Profit Margin
Major Pharmaceutical Preparations Industry Gross Profit Margin Trends and Statistics
Healthcare Sector Gross Profit Margin Statistics
Gross Profit Margin Profitability Trends for overall market
VANC's Gross Profit Margin Profitability versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Gross Profit Margin
Lowest Ranking Gross Profit Margin
Gross Profit Margin Profit Margin for VANC's Competitors
Gross Profit Margin Profit Margin for Avricore Health Inc 's Suppliers
Gross Profit Margin Profit Margin for VANC's Customers

You may also want to know
VANC's Annual Growth Rates VANC's Profitability Ratios VANC's Asset Turnover Ratio VANC's Dividend Growth
VANC's Roe VANC's Valuation Ratios VANC's Financial Strength Ratios VANC's Gross Profit Growth
VANC's Roa VANC's Inventory Turnover Ratio VANC's Growth Rates VANC's Dividend Comparisons


Companies with similar Gross Profit Margin in the quarter ending Dec 31 2024, within Major Pharmaceutical Preparations Industry Gross Profit MarginDec 31 2024 MRQ Gross ProfitDec 31 2024 MRQ Revenue
Bioadaptives Inc   100.00 %$ 0.001  Millions$ 0.001  Millions
Pulmatrix Inc   100.00 %$ 0.003  Millions$ 0.003  Millions
Macrogenics Inc   98.80 %$ 19.120  Millions$ 19.353  Millions
Lexicon Pharmaceuticals Inc   98.69 %$ 26.206  Millions$ 26.554  Millions
Lexaria Bioscience Corp   98.52 %$ 0.181  Millions$ 0.184  Millions
Corcept Therapeutics Inc  98.37 %$ 178.934  Millions$ 181.890  Millions
Ionis Pharmaceuticals Inc   98.31 %$ 222.747  Millions$ 226.577  Millions
Travere Therapeutics Inc   96.59 %$ 72.234  Millions$ 74.787  Millions
Emmaus Life Sciences Inc   96.51 %$ 2.983  Millions$ 3.091  Millions
Cormedix Inc   96.23 %$ 30.034  Millions$ 31.210  Millions
Gyre Therapeutics Inc   95.78 %$ 26.695  Millions$ 27.872  Millions
Karyopharm Therapeutics Inc   95.64 %$ 29.211  Millions$ 30.542  Millions
Vanda Pharmaceuticals Inc   95.13 %$ 50.595  Millions$ 53.185  Millions
Blueprint Medicines Corporation  94.91 %$ 138.920  Millions$ 146.367  Millions
Madrigal Pharmaceuticals Inc   93.97 %$ 97.087  Millions$ 103.320  Millions
Ocular Therapeutix Inc   92.80 %$ 15.853  Millions$ 17.083  Millions
Blue Water Vaccines Inc  92.70 %$ 0.660  Millions$ 0.712  Millions
Aclaris Therapeutics Inc   92.35 %$ 8.505  Millions$ 9.210  Millions
Innoviva Inc   92.05 %$ 82.975  Millions$ 90.140  Millions
Ascendis Pharma A  91.97 %$ 172.050  Millions$ 187.071  Millions
Silence Therapeutics Plc  91.95 %$ 23.267  Millions$ 25.305  Millions
Silo Pharma Inc  91.90 %$ 0.017  Millions$ 0.018  Millions
Acadia Pharmaceuticals Inc   91.60 %$ 237.799  Millions$ 259.602  Millions
Regeneron Pharmaceuticals Inc   91.38 %$ 3,462.400  Millions$ 3,789.200  Millions
Optinose Inc   91.28 %$ 20.465  Millions$ 22.419  Millions
Rhythm Pharmaceuticals Inc   90.95 %$ 38.044  Millions$ 41.830  Millions
Aurinia Pharmaceuticals Inc   90.73 %$ 54.315  Millions$ 59.867  Millions
Arcutis Biotherapeutics Inc   90.32 %$ 64.455  Millions$ 71.360  Millions
Amicus Therapeutics inc   90.09 %$ 134.870  Millions$ 149.706  Millions
Rigel Pharmaceuticals Inc  89.95 %$ 51.807  Millions$ 57.596  Millions




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.